<DOC>
	<DOCNO>NCT01790607</DOCNO>
	<brief_summary>To evaluate compare pharmacokinetics safety ONO-2745/CNS 7056 subject hepatic impairment match healthy subject .</brief_summary>
	<brief_title>An Open-label , Single-dose , Intravenous Administration Study ONO-2745/CNS 7056 Subjects With Chronic Hepatic Impairment</brief_title>
	<detailed_description>In Part One , 8 subject moderate hepatic impairment ( Child Pugh Scale B ) 8 match healthy subject enrol . In Part 2 , 8 subject mild hepatic impairment ( Child-Pugh Scale A ) 8 match healthy subject enrol . In Part 3 , 3 subject severe hepatic impairment ( Child-Pugh Scale C ) enrol . Parts 2 3 initiated criterion per protocol meet Part One . The pharmacokinetics safety profile compare hepatic impaired subject healthy subject .</detailed_description>
	<mesh_term>Liver Diseases</mesh_term>
	<criteria>Males females 18 65 year age Negative test select drug abuse screen Hepatic impaired subject : Stable hepatic function medication regimen least 28 day prior checkin Degree hepatic impairment determine ChildPugh Scale Clinical manifestation disease ( except hepatic impaired subject ) History significant hypersensitivity , intolerance , allergy drug compound , include food , substance</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Adult healthy subject match individual subject age ( ± 5 year , gender , BMI ( ± 15 % )</keyword>
</DOC>